Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Company Deals

Bristol-Myers Squibb Partners With Anthropic to Deploy Claude AI Across Enterprise, Signaling Strategic Shift to Agentic Workflows

Fineline Cube May 21, 2026
Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Fineline Cube May 21, 2026
Company Drug

Mabwell Bioscience Secures Second NMPA Approval for Denosu Biosimilar, Expanding Indication to Bone Metastases and Multiple Myeloma

Fineline Cube May 21, 2026
Company

Viatris Posts Q3 2025 Revenue Dip, Highlights Emerging‑Market Branded Growth and Aculys Pharma Acquisition

Fineline Cube Nov 8, 2025

U.S.‑based Viatris Inc. (NASDAQ: VTRS) released its third‑quarter 2025 earnings, showing a 2 % year‑over‑year (YOY)...

Company Drug

Humanwell Healthcare Secures NMPA Approval to Launch First Fixed‑Dose Combination for Pulmonary Arterial Hypertension

Fineline Cube Nov 8, 2025

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its investigational compound HWH217 has received...

Company Drug

Eli Lilly & Novo Nordisk Reach U.S. Deal to Cut Obesity‑Drug Prices, Unlock Medicare & Medicaid Access

Fineline Cube Nov 8, 2025

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) announced a historic agreement with the...

Medical Device

Johnson & Johnson Launches ETHICON 4000 3D Laparoscopic Stapler in China

Fineline Cube Nov 8, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced today the commercial rollout of its ETHICON 4000 laparoscopic stapler...

Company

BeOne Medicines Posts $1.4 B Q3 2025 Revenue, Driven by BRUKINSA Momentum

Fineline Cube Nov 7, 2025

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released its third‑quarter 2025 financial results, reporting...

Company Drug

CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA​I Meeting

Fineline Cube Nov 7, 2025

China‑based CStone Pharmaceuticals (HKG: 2616) announced that the pre‑clinical results for its bispecific biologic CS2015...

Company Deals

AmacaThera Signs Exclusive Global License with Pacira BioSciences for AMT‑143, Up to $230 M Deal

Fineline Cube Nov 7, 2025

AmacaThera, the hydrogel‑technology biotech incubated by Viva BioInnovator (VBI), announced an exclusive worldwide licensing agreement...

Others

Sanofi’s Cablivi Wins China NMPA Approval – First Nanobody Drug for aTTP

Fineline Cube Nov 7, 2025

Sanofi (NASDAQ: SNY) announced that its anti‑vWF Nanobody Cablivi (caplacizumab for injection) received formal marketing...

Others

Judge Rejects Pfizer’s Attempt to Block Novo Nordisk’s $10 bn Bid for Metsera

Fineline Cube Nov 7, 2025

Delaware Court of Chancery Judge Morgan Zurn denied Pfizer’s (NYSE: PFE) request for a temporary...

Company

Amgen Reports 12% YoY Sales Growth in Q3 2025, Raises Full‑Year Revenue Guidance

Fineline Cube Nov 7, 2025

US‑based biotech giant Amgen (NASDAQ: AMGN) posted its third‑quarter 2025 results, showing total sales of...

Company

AstraZeneca Posts 11% Y/Y Revenue Rise to $43.24 bn in First Nine‑Months of 2025

Fineline Cube Nov 7, 2025

AstraZeneca (AZ, NASDAQ: AZN) released its third‑quarter and nine‑month 2025 financial results, showing total revenues...

Policy / Regulatory

NHSA Concludes 2025 National Basic Medical Insurance Drug Catalogue Negotiation and Commercial Insurance Innovative Drug Price Talks

Fineline Cube Nov 6, 2025

The National Healthcare Security Administration (NHSA) wrapped up a week‑long series of negotiations and bidding...

Company Deals

XtalPi’s Ailux Strikes $345 Million Partnership with Eli Lilly to Co‑Develop Bispecific Antibodies

Fineline Cube Nov 6, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) disclosed that its wholly‑owned subsidiary Ailux...

Medical Device

Siemens Shanghai Gains NMPA Clearance for Prostate‑Cancer AI Detection Software

Fineline Cube Nov 6, 2025

Siemens Shanghai Medical Equipment Ltd. (SSME) announced that the National Medical Products Administration (NMPA) has...

Company Deals

HBM’s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co‑Develop In‑Vivo CAR‑T Platforms

Fineline Cube Nov 6, 2025

HBM Holdings Limited (HKG: 2142) announced that its wholly‑owned subsidiary Nona Biosciences (Suzhou) Co., Ltd....

Company Deals

Shandong Jincheng Pharma Subsidiary Jincheng Taier to Sell Proxyl Vaginal Capsule Tech & MAH Rights to Shanghai Hemony for RMB 50 M

Fineline Cube Nov 6, 2025

Shandong Jincheng Pharmaceutical Group Co., Ltd. (SHE: 300233) disclosed that its wholly‑owned subsidiary Jincheng Taier...

Company Drug

Sinotau Receives FDA NDA Approval for MK‑6240 Tau PET Imaging Agent

Fineline Cube Nov 6, 2025

Beijing Sinotau International Pharmaceutical Technology Co., Ltd. announced today that the New Drug Application (NDA) for...

Company Deals

Baheal Pharma Locks CSL Behring Albumin Rights to Boost China’s Blood Product Supply

Fineline Cube Nov 6, 2025

Baheal Pharma Group (SHE: 301015), a prominent Chinese therapeutic manufacturer, announced an enhanced cooperation agreement...

Company Deals

Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused

Fineline Cube Nov 5, 2025

Prelude Therapeutics (NASDAQ: PRLD) unveiled a suite of strategic shifts: it signed an option deal...

Company Drug

UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d

Fineline Cube Nov 5, 2025

UCB (EBR: UCB) announced that KYGEVVI received FDA approval for the treatment of adult and...

Posts pagination

1 … 86 87 88 … 669

Recent updates

  • Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up
  • Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network
  • Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma
  • Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy
  • Mabwell Bioscience Secures Second NMPA Approval for Denosu Biosimilar, Expanding Indication to Bone Metastases and Multiple Myeloma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Company Medical Device

Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.